403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Biovaxys Technology Corp
(MENAFN- Baystreet) 09:45 AM EST - BioVaxys Technology Corp: Announced the acceptance of an abstract related to the PESCO study, an investigator-initiated, open-label, non-randomized phase 1B/2 trial to evaluate the safety and efficacy of combination of BioVaxys' MVP-S with pembrolizumab (KeytrudaTM) and cyclophosphamide in patients with recurrent epithelial ovarian cancer for presentation at the American Society of Clinical Oncology Annual Meeting, taking place in Chicago, May 29th-June 6th, 2026. BioVaxys Technology Corp
shares C are trading unchanged at $0.05.
Full Press Release:
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
Comments
No comment